Researchers at Baylor College of Medicine discovered that the use of drug Zotatifin to target protein elF4A in testing on triple-negative breast cancer (TNBC) animal models suppressed tumour growth and improved the immune microenvironment of the tumour. These findings indicate a potential new avenue for TNBC treatment, with the possibility of clinical trials to assess patient benefits.
“An Expensive Problem”: Cracking the Cyber Insurance Conundrum
Rampant ransomware attacks have hit the healthcare industry, with incidents increasing by more than 600%, costing an average of $10 million per breach. This has
